The usefulness of estrogen receptor measurements in primary breast tumors in the prediction of early recurrence was examined in a series of 145 patients. The absence of estrogen receptor in such tumors was associated with early recurrence independent of other known prognostic factors such as axillary lymph node status and tumor size.


Supported in part by the National Cancer Institute (CB 23862) and the Mead Johnson Company.

This content is only available via PDF.